Title: Factors Associated With Serious Adverse Events and Misuse of Glp-1 Receptor Agonists 

Chair: Dr. Alexander Kirpich 

Abstract: This study investigates the factors associated with the serious adverse event (SAE) outcomes and misuse of GLP-1 Receptor Agonists (GLP-1RAs), a prominent medication for type-2 diabetes and obesity, using data from the FDA Adverse Event Reporting System (FAERS) from 2005 to 2023. With projected increases in GLP-1RA use by 2025 and growing concerns about misuse and counterfeit products, more research is needed to understand these risk factors. Using multinomial logistic regression for SAE outcomes and logistic regression for misuse on a sample of 20,704 reports, the study found that each additional year in age decreased the odds of non-fatal SAEs, females had lower odds of fatal SAEs, and Semaglutide was associated with higher odds of death/life-threatening outcomes. Misuse was linked to higher odds of hospitalization, with reports submitted by female consumers had increasing misuse odds, while older age reduced these odds. Thus, these findings highlight a need for age- and gender-specific risk assessment in GLP-1RA therapy. While the study's strengths include its relatively large sample size and statistical approaches, limitations such as potential reporting bias could warrant further research using more comprehensive data sources. The increasing utilization of GLP-1RAs and associated SAEs necessitate attention from public health agencies, particularly given the ongoing development of more convenient administration methods.